CompetitionAmazon launched a cash-pay telehealth service and treatment offering that could compete directly with HIMS.
Pricing PressureAmazon is offering much more compelling prices than HIMS on most treatments, posing a threat to HIMS’ core offering.
Regulatory UncertaintyThe FDA reviewing its decision to remove tirzepatide from the shortage list shows that the question of potential duration for HIMS' compounded GLP-1s sales, and the inherent uncertainties around supply shortages, will remain in focus and continue to cause stock volatility.